Readers and Tweeters Chime In on Disability Rights and Drug Discounts
KHN gives readers a chance to comment on a recent batch of stories.
Drugs
341-360 of 1,323 results
-
-
Is Legislation to Safeguard Americans Against Superbugs a Boondoggle or Breakthrough?
While supporters cheer the PASTEUR Act as an essential strategy to stem the rise of antibiotic-resistant pathogens, critics call it a multibillion-dollar giveaway to Big Pharma.
By Liz Szabo and Arthur Allen -
KHN鈥檚 鈥榃hat the Health?鈥: Health Spending? Only Congress Knows
Top negotiators in Congress have agreed to a framework for government spending into next year, but there are details to iron out before a vote 鈥 such as the scheduled Medicare payment cuts that have providers worried. Also, the Biden administration reopens its program allowing Americans to request free covid-19 home tests, as hopes for pandemic preparedness measures from Congress dim. Rachel Cohrs of Stat, Alice Miranda Ollstein of Politico, and Rebecca Adams of KHN join KHN鈥檚 Mary Agnes Carey to discuss these topics and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.
-
States Challenge Biden to Lower Drug Prices by Allowing Imports From Canada
Colorado has joined Florida, New Hampshire, and New Mexico in seeking federal permission to import prescription drugs from Canada. President Joe Biden endorsed the approach in his 2020 campaign but has yet to approve any state plan.
-
In Rural America, Deadly Costs of Opioids Outweigh the Dollars Tagged to Address Them
Some people say it鈥檚 reasonable for densely populated areas to receive more settlement funds, since they serve more of those affected. But others worry this overlooks rural communities disproportionately harmed by opioid addiction.
By Aneri Pattani and Rae Ellen Bichell -
KHN鈥檚 鈥榃hat the Health?鈥: Congress Races the Clock
Sen. Raphael Warnock鈥檚 re-election in Georgia will give Democrats a clear-cut Senate majority for the first time in nearly a decade. Meanwhile, the current Congress has only days left to tackle major unfinished business on the health agenda, including fending off scheduled pay cuts for doctors and other health providers in the Medicare program. Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, Anna Edney of Bloomberg News, and Sandhya Raman of CQ Roll Call join KHN鈥檚 Julie Rovner to discuss these topics and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.
-
Paxlovid Has Been Free So Far. Next Year, Sticker Shock Awaits.
The government soon will stop paying for the covid drug that has proved to be the most effective at keeping patients alive and out of the hospital.
By Hannah Recht -
Employers Use Patient Assistance Programs to Offset Their Own Costs
Some insurers and employers are tapping into assistance programs meant for individual patients. The concern: Some costly drugs could be harder for patients to access.
-
Journalists Discuss Medicaid Rules, Opioid Settlement Funds, and the Public Health Workforce
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here鈥檚 a collection of their appearances.
-
The Business of Clinical Trials Is Booming. Private Equity Has Taken Notice.
Private equity-backed Headlands Research heralded its covid-19 vaccine trials as a chance to boost participation among diverse populations, then it shuttered multiple sites that conducted them.
-
Watch: The Politics of Health Care in California
KHN senior correspondent Angela Hart discussed the most pressing health care issues in California with the nonpartisan group Democracy Winters in mid-November, touching on a variety of issues, from the state鈥檚 effort to transform its Medicaid program to its plan to produce generic insulin.
-
KHN鈥檚 鈥榃hat the Health?鈥: Medicaid Machinations
The lame-duck Congress has returned to Washington with a long health care to-do list and only a little time. Meanwhile, some of the states that have not yet expanded Medicaid eligibility under the Affordable Care Act are rethinking those decisions. Alice Miranda Ollstein of Politico, Rachel Cohrs of Stat, and Sarah Karlin-Smith of the Pink Sheet join KHN鈥檚 Julie Rovner to discuss these topics and more. Also this week, Rovner interviews KHN鈥檚 Fred Clasen-Kelly, who reported and wrote the latest KHN-NPR 鈥淏ill of the Month鈥 feature, about a mysterious mishap during minor surgery.
-
Readers and Tweeters Decry Medical Billing Errors, Price-Gouging, and Barriers to Benefits
KHN gives readers a chance to comment on a recent batch of stories.
-
Schools, Sheriffs, and Syringes: State Plans Vary for Spending $26B in Opioid Settlement Funds
The cash represents an unprecedented opportunity to derail the opioid epidemic, but with countless groups advocating for their share of the pie, the impact could depend heavily on geography and politics.
-
Pfizer鈥檚 Covid Cash Powers a 鈥楳arketing Machine鈥 on the Hunt for New Supernovas
While sales of its covid vaccines are falling, Pfizer plans to triple the price of the shots and use its bonanza from government contracts to buy and develop new blockbusters.
By Arthur Allen -
Defense Department Health Plan Cuts Its Pharmacy Network by Nearly 15,000 Outlets
Many of the pharmacies were small, independent operations that had decided not to participate next year because of the lowered reimbursement being offered. But they were surprised by an early dismissal, and some patients with specialized drug needs could face difficulties in the transition.
-
Readers and Tweeters Take Positions on Sleep Apnea Treatment
KHN gives readers a chance to comment on a recent batch of stories.
-
$38,398 for a Single Shot of a Very Old Cancer Drug
Lupron, a drug patented half a century ago, treats advanced prostate cancer. It鈥檚 sold to physicians for $260 in the U.K. and administered at no charge. Why are U.S. hospitals 鈥 which may pay nearly as little for the drug 鈥 charging so much more to administer it?
By Arthur Allen -
KHN鈥檚 鈥榃hat the Health?鈥: Biden Hits the Road to Sell Democrats鈥 Record
With the midterm elections rapidly approaching, President Joe Biden has taken to the road to convince voters that he and congressional Democrats have delivered for them during two years in power. Among the health issues highlighted by the administration this week are pandemic preparedness and the availability of over-the-counter hearing aids. The president also promised to sign a bill codifying the abortion protections of Roe v. Wade if Democrats maintain control of the House and Senate 鈥 even though it鈥檚 a long shot that there will be enough votes for that. Sarah Karlin-Smith of the Pink Sheet, Sandhya Raman of CQ Roll Call, and Mary Agnes Carey of KHN join KHN鈥檚 Julie Rovner to discuss these topics and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.
-
As Links to MS Deepen, Researchers Accelerate Efforts to Develop an Epstein-Barr Vaccine
Recent leaps in medical research have lent urgency to the quest to develop a vaccine against Epstein-Barr, a ubiquitous virus that has been linked to a range of illnesses, from mononucleosis to multiple sclerosis and several cancers.
By Liz Szabo